EARLY ACS-TIMI 39

EARLY ACS-(TIMI 39) assessed the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST segment elevation acute coronary syndrome.

DOWNLOAD SLIDE SET (PDF)

Key Study Publications

Giugliano, R. P., White, J. A., Bode, C., Armstrong, P. W., Montalescot, G., Lewis, B. S., van 't Hof, A., Berdan, L. G., Lee, K. L., Strony, J. T., Hildemann, S., Veltri, E., Van de Werf, F., Braunwald, E., Harrington, R. A., Califf, R. M., Newby, L. K. Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med. 2009;360(21):2176-90. Abstract